Open for feedback
Clozapine: Proposed changes to blood monitoring and prescribing requirements - consultation questions for consumers and families
This Medsafe consultation seeks your feedback on proposed changes to the blood monitoring for clozapine. We are running this consultation on behalf of the companies that distribute clozapine-containing medicines in New Zealand. Clozapine is an antipsychotic medicine used to treat schizophrenia that has not responded to other antipsychotics (treatment-resistant schizophrenia). For safety reasons, there are restrictions around clozapine use in New Zealand and other countries. In some...
Clozapine: Proposed changes to blood monitoring and prescribing requirements - consultation questions for healthcare professionals
This Medsafe consultation seeks your feedback on proposed changes to the blood monitoring and prescribing requirements for clozapine. We are running this consultation on behalf of the companies that distribute clozapine-containing medicines in New Zealand. Clozapine is an antipsychotic medicine used in treatment-resistant schizophrenia. To increase the safety of people taking clozapine, there are restrictions on use of the medicine in New Zealand. In some people, clozapine can...
Closed for feedback
Topical corticosteroids: Proposal for the package labelling to state their potency
Medsafe is seeking your feedback on a proposed advisory statement for topical corticosteroids to include information about the potency (strength) on the container/package label. In March...
Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Bioequivalence of medicines
This consultation is aimed at pharmaceutical companies seeking to demonstrate bioequivalence of medicines to support applications to Medsafe for regulatory approval of new and changed products....
Putting Patients First: Modernising health workforce regulation
The Government is inviting New Zealanders to share their views on health workforce regulation by 11.59 pm Wednesday 30 April. On 28 March 2025, the Ministry published a...
Consultation on safety measures for the use of puberty blockers in young people with gender-related health needs
The consultation on safety measures for the use of puberty blockers in young people with gender-related health needs closed on 20 January 2025. We will now consider submissions. Background ...
Unlocking the potential of active ageing - Long-term Insights Briefing publication consultation
The Ministry of Health – Manatū Hauora is seeking written feedback on the proposed topic of its Long-term Insights Briefing by Monday 2 December 2024. Our proposed Long-term Insights Briefing...
Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Clinical Trials
This consultation is aimed at pharmaceutical companies, health care professional organisations and individuals involved in conducting clinical trials in New Zealand. People who participate in...